Acute Cholangitis — TG18 Grade-Ladder Drainage Timing, Short-Course Antibiotics and Index Cholecystectomy Arithmetic

Definition and framing — obstruction plus infection, and an emergency

Acute bacterial cholangitis is, for the most part, a stone disease of the common bile duct that turns potentially life-threatening: fever, abdominal pain and jaundice (Charcot triad), with confusion and septic shock marking the Reynolds pentad end of the spectrum.^[1] Hold the two-component doctrine in one hand at every bedside: bacterial infection demanding immediate antimicrobial therapy, and bile-duct obstruction demanding biliary drainage — transpapillary endoscopic drainage by stent or nasobiliary drain, with or without same-session duct clearance, is first-line, tuned to disease severity.^[1] Both endoscopy societies agree on the urgency framing: cholangitis is a gastrointestinal emergency requiring prompt recognition and treatment, and in that setting biliary decompression can be lifesaving.^[2][3]

Etiology and epidemiology — stones first, stenosis next

The etiology ladder is short: stones are the primary cause of acute cholangitis, and next to stones the most significant cause is benign or malignant stenosis of the biliary tract.^[4] The stone reservoir is large — common bile duct stones are estimated in 10 to 20% of people with symptomatic gallstones.^[5] In hospital cohorts the split is concrete: choledocholithiasis caused 31.9% of obstructions against 21.0% from mass or malignancy in 193 patients and 229 encounters, while the Icelandic population series of 240 patients (median age 74, 45% women) was 75% gallstone and 19% malignant disease.^[6][7] Mortality has fallen across eras but never to background: about 10% after 2000 in the TG13 review against under 1% for cholecystitis, down to 3.3% 30-day mortality in the modern 240-patient series and 1.9% pooled in-hospital mortality across the timing meta-analysis.^[4][7][24]

Diagnosis and severity — the TG18 validation and the Grade II signal

The TG13 diagnostic criteria found more true cholangitis than TG07, and higher TG13 severity predicted significantly higher 30-day mortality across Japanese and Taiwanese big data — which is why the TG13 criteria were adopted as the TG18 diagnostic and severity standard for routine clinical use.^[8] The severity grade is not decorative: comparing early or urgent drainage against none showed no 30-day mortality difference in Grade I or Grade III disease, but significantly lower mortality in Grade II patients who received early or urgent drainage — so the grade both flags whose prognosis drainage can improve and predicts outcome.^[8] Say at the viva what this evidence set cannot support: there is no standalone severity-prediction score in the kept abstracts, so quote the validation, the shock physiology split, and the bacteremia-by-grade ladder — never an invented points system.^[8][12][23]

Initial management and bundles — the grade ladder

Start every suspected biliary infection the same way: vital signs first to judge urgency, resuscitation before diagnosis when the case is urgent, then history, examination, bloods, urinalysis and imaging, diagnosis by criteria, and immediate treatment with severity grading and a general-status check.^[9] Then climb the ladder: mild disease usually needs only initial treatment including antibiotics, with most patients never requiring drainage — but reconsider drainage on non-response; moderate disease earns early endoscopic or percutaneous drainage, with etiology treated after recovery and sphincterotomy plus stone clearance combinable with the drainage; severe disease demands respiratory and circulatory management first, with drainage as soon as possible once the patient is stabilized.^[9] The bundles spine behind the ladder is four items: diagnostic process, severity assessment, transfer when necessary, and the therapeutic approach at each time point — observance should improve prognosis.^[10] The compliance audit keeps the ladder honest: across 60,842 Japanese patients (mild 49,630, moderate 10,444, severe 768), adherence scores ran 7.6 for severe against 6.5 for moderate and only 2.9 for mild — the better the patient looks, the more often doctrine is skipped.^[11]

Bacteremia and blood cultures — collect regardless of grade

Bacteremia is the rule to exclude, not the exception: in 358 emergency patients, cultures were drawn in 310 (87%) and 148 (48%) were bacteremic — rising cleanly with TG18 grade from 35% in Grade I (59 of 171) to 59% in Grade II (48 of 82) to 74% in Grade III (42 of 57).^[12] The trap for the viva: agreement with TG18 diagnostic certainty did not differ between bacteremic and non-bacteremic patients, and 36% of patients with unfulfilled criteria (14 of 39) were still bacteremic — so blood cultures go in regardless of severity or diagnostic certainty.^[12] Pus itself is a severity marker: among 401 patients, 102 had suppurative bile, and suppurative bile carried 79.7% specificity for moderate-to-severe disease — with concurrent cholecystitis, CRP, procalcitonin, total bile acids and bile-duct diameter as the independent predictors of suppuration.^[13]

Biomarkers — what procalcitonin cannot do

Procalcitonin disappoints as a routine severity gate: in 193 patients across 229 encounters (only 40.2% undergoing ERCP, with percutaneous drainage in 21.8% and conservative care in 34.5%), procalcitonin was non-superior to lactate with low predictive values for in-hospital mortality, ICU admission or need for early decompression.^[6] Keep the one exception fenced: in malignancy-related cholangitis, procalcitonin did beat lactate for mortality, ICU admission and early-decompression prediction — a subgroup signal that does not generalize to stone disease.^[6] For the bedside, this means severity grading and shock physiology — not a single biomarker — set the drainage clock.^[8][23]

Antimicrobials — TG18 doctrine and the short-course turn

Empirical cover follows the TG18 listing: agents by class-definition and severity grade I through III, split by community-acquired versus healthcare-associated setting, with local antibiograms monitored and updated as resistance evolves.^[14] Stewardship is doctrine, not decoration: prudent use with early de-escalation or termination once isolates return — and duration itself was systematically reviewed as new in TG18.^[14] One deletion to announce at the station: prophylactic antimicrobials for elective ERCP are no longer recommended, and the section was removed.^[14] After successful drainage, shorter is supported from four directions: the 120-patient moderate/severe RCT found 4-day therapy noninferior to 8-day on clinical cure (79.66% against 77.97%, P equals 0.822) with post-intervention days nearly halved (8.58 against 4.75), while malignant etiology and hypotension at presentation predicted lower cure.^[15] The Dutch multicenter retro of 296 drained stone-cholangitis patients found therapy of 3 days or less (137 patients, 46.3%) sufficient — local infectious complications 13.9% with no between-group difference (p equals 0.32) and a day less in hospital (6 against 7 days, p equals 0.03).^[16] The systematic review of 205 patients found no mortality or post-ERCP fever difference, with one study even favouring short course on recurrence (0.0% against 13.3%) and shorter stay (14 against 17.5 days) — while still calling for proper randomised trials.^[17] And two lightening strategies held: early oral switch in bacteremic drained patients (29 against 30) eradicated bacteria equally (93.1% against 93.3%, noninferior to 10-day intravenous therapy), and blood-culture-alone adjustment (215 against 213) matched blood-plus-bile on organ failure (13.0% against 12.7%) and mortality (3.3% against 2.3%).^[18][19] The Colombian 317-patient cohort agrees with a warning attached: short course (59 patients, 4 days or less) matched long course (258 patients) on the mortality/ICU/readmission composite — but Tokyo Grade III carried 32-fold odds and carbapenem resistance 4-fold odds for that composite, so severity and resistance still overrule the calendar.^[20]

Drainage modality — endoscopic first, percutaneous in reserve

The ASGE position is two lines: endoscopic over percutaneous drainage with decompression within 48 hours, and sphincterotomy plus stone removal combined with the drainage — unless the patient is too unstable to tolerate the fuller endoscopic treatment.^[2] The technical detail underneath: nasobiliary-tube and plastic-stent drainage give comparable outcomes, chosen case by case, and sphincterotomy is basically unnecessary for drainage alone — though single-session sphincterotomy with stone removal is acceptable in mild-to-moderate cases without antithrombotic therapy or coagulopathy.^[21] The ACR frame covers the failures and the anatomy: percutaneous, endoscopic and surgical decompression are selected by etiology, patient factors and individual anatomy — and where stones prove irretrievable, ESGE temporizes with a plastic stent.^[3][22] For difficult stones, the examined first line is limited sphincterotomy combined with large-balloon dilation of the papilla.^[22]

Timing by grade — the ESGE clock and the shock line

Set the clock by grade, ESGE style: severe disease — as soon as possible and within 12 hours for septic shock; moderate disease — within 48 to 72 hours; mild disease — electively.^[22] TG18 marches in step: early drainage for moderate disease, resuscitate-then-drain-as-soon-as-possible for severe disease, antibiotics-first with drainage on non-response for mild disease — with transpapillary drainage within 24 hours as the standing recommendation for moderate-to-severe presentations.^[9][21]

Timing outcomes — pooled, matched, national, and the paradox

The pooled ledger favours earlier drainage with unusual consistency: 14 observational studies with 84,063 patients (mean age 66) give pooled in-hospital mortality 1.9%, rising to 4.3% without administrative-database studies — and mortality odds falling at every cut-point (under 24 hours OR 0.81, under 48 hours OR 0.57, under 72 hours OR 0.32) with stays shorter by 3.2, 3.6 and 4.1 days respectively.^[24] The propensity-matched stone cohort sharpens the bedside contrast: 191 matched pairs, urgent drainage within 24 hours cutting in-hospital mortality from 21% to 0.5% (adjusted OR 0.09) and stay from 8 to 5 days at equal stone clearance near 75% — with the mortality benefit confined to moderate and severe disease and absent in mild cases.^[25] National data set the outer guardrails: among 91,051 cholecystectomy admissions for cholangitis, mortality stayed under 1% when ERCP fell within 3 days but rose with delay (over 72 hours adjusted OR 1.80, and 1.88 within Grade III) — while the 240-patient population series found early-versus-late mortality statistically indistinguishable (4.9% against 2.5%) yet stay shorter with early ERCP (4 against 6 days).^[26][7] Then teach the paradox that catches examiners out: in 271 choledocholithiasis patients, mortality read highest in the within-24-hours arm (16.7% against 5.6% against 6.6%) — but age and comorbidity burden above 5 were the independent predictors, and residual confounding by indication cannot be excluded, because the sickest patients are rushed first.^[27] The honest close of this section: every timing number above is observational, and the meta-analysts themselves call for the randomised trial of urgent ERCP.^[24]

Septic shock — the physiology that moves first

In vasopressor-dependent cholangitis, physiology predicts before anatomy is fixed: non-survivors carried higher APACHE II scores (28 against 22) and higher admission lactate (4.6 against 3.4 mmol per litre) than survivors.^[23] Two delays killed: appropriate antimicrobials at a median 6.8 hours from shock in non-survivors against 2.6 hours in survivors (each hour adding 15% adjusted odds of death), and successful decompression at 22 against 8.8 hours.^[23] Run the shock sequence as resuscitation, antimicrobials within hours, successful decompression within 12 hours of shock onset — then short-course antibiotics once drainage is secured.^[23][15]

Definitive clearance — do not leave the gallbladder by default

Drainage treats the episode; cholecystectomy prevents the encore. Among 124,964 gallstone-cholangitis admissions, only 14.67% received same-admission cholecystectomy — and their 30-day all-cause readmission was roughly half (5.56% against 11.50%), with sepsis the leading cause in both arms and cholangitis itself second where surgery was deferred.^[29] The concurrent-disease study removes the operative-fear objection: in 147 patients with cholecystitis plus cholangitis after successful ERCP drainage, same-admission surgery cut recurrent biliary events from 41.2% to 5.2% with no difference in transfusion, conversion, complications, operating time or post-operative stay.^[30] Two windows carry the timing: ESGE sets cholecystectomy within 2 weeks of ERCP for choledocholithiasis to cut conversion and recurrent events, and the 112-patient post-cholangitis series shows why delay hurts — surgery beyond 6 weeks raised intraoperative complications (28.8% against 9.4%) and post-operative complications (42.5% against 15.6%), with late surgery an independent risk alongside prior sphincterotomy.^[22][31]

Elderly, frail, and malignant-obstruction fences

Expect atypical disease past 75: Charcot triad in only 4.2% with comorbidity in a third — yet urgent drainage within 24 hours in 80.5% held mortality to 1.5%, tied to drainage success and severity grade rather than to age itself.^[28] Frailty, not years, prices the ERCP: among 5751 cholangitis-with-stone admissions (mean age 69.4), 89.2% underwent therapeutic ERCP and 38.0% were frail — with post-ERCP complications 14.63% against 6.20%, plus longer stays, higher cost and higher mortality risk, though readmission did not rise.^[32] For the unfit with the gallbladder still in situ, the wait-and-see ledger reassures: 450 patients aged 75 or older (median 85) followed a median 36 months after endoscopic stone extraction without cholecystectomy — 11% recurrent biliary events at a median 307 days, mostly cholecystitis (7.1%) with cholangitis in only 2.7% and pancreatitis in 0.4%, and later surgery or endoscopy carried no deaths.^[33] Fence the malignant adjunct where it belongs: EUS-guided against ERCP-guided drainage for malignant obstruction (6 randomised trials, 577 patients) matched on technical and clinical success but cut post-procedure pancreatitis (RR 0.15), reintervention (RR 0.57) and stay (1.03 days) — malignant doctrine only, never quoted for stone cholangitis in this topic.^[34]

Revision summary

Cholangitis is obstructed, infected bile — a gastrointestinal emergency where decompression can be lifesaving; stones cause most cases with stenosis next, and modern mortality runs 2 to 3% against 10% historically.^{[1][2][3][4][7]} Grade the disease because the grade sets the clock: mild disease takes antibiotics with drainage on non-response, moderate disease takes early drainage, severe disease takes resuscitation then drainage as soon as possible — with Grade II the group whose mortality drainage demonstrably improves.^[9][8] Culture blood in everyone including unfulfilled-criteria cases, list empirical cover by grade and setting with early de-escalation, and stop antibiotics short once drainage succeeds — 4 days matching 8, and 3 days or less sufficing after successful ERCP.^{[12][14][15][16]} Drain endoscopically within 48 hours, faster for higher grades and within 12 hours of shock onset — earlier drainage cutting mortality and days across 84,000 pooled patients, read the within-24-hours paradox as confounding by indication, and finish the job with index or early cholecystectomy that halves readmission.^{[2][22][23][24][27][29]}

AUC 0.875, sensitivity 86.6%, specificity 75.5% for suppurative bile — but Grade II/III diagnosis of ASC still risks missed cases at 60.8% sensitivity (PMID 39304833).^[13]

no standalone severity-prediction abstract survived — quote only the TG18 validation, the shock APACHE/lactate split (22 vs 28; 3.4 vs 4.6 mmol/L), and the bacteremia-by-grade ladder, never an invented score (PMIDs 29032610, 27506331, 34635451).^[23]

References34ShowHide

1. [1]Zimmer V, Lammert F Acute Bacterial Cholangitis. Viszeralmedizin, 2015.PMID 26468310
2. [2]Buxbaum JL, Buitrago C, Lee A, et al. ASGE guideline on the management of cholangitis. Gastrointest Endosc, 2021.PMID 34023065
3. [3]Fairchild AH, Hohenwalter EJ, Gipson MG, et al. ACR Appropriateness Criteria(®) Radiologic Management of Biliary Obstruction. J Am Coll Radiol, 2019.PMID 31054746
4. [4]Kimura Y, Takada T, Strasberg SM, et al. TG13 current terminology, etiology, and epidemiology of acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci, 2013.PMID 23307004
5. [5]Williams E, Beckingham I, El Sayed G, et al. Updated guideline on the management of common bile duct stones (CBDS). Gut, 2017.PMID 28122906
6. [6]Kozai LA, Nishimura Y, Czech T, et al. Serum Procalcitonin as an Indicator of Disease Severity and Clinical Deterioration in Hospitalized Patients With Acute Cholangitis. Cureus, 2025.PMID 40951025
7. [7]Fridgeirsson HF, Konradsson M, Vesteinsdottir E, et al. Incidence and outcomes in patients with acute cholangitis: a population-based study. Scand J Gastroenterol, 2023.PMID 37409689
8. [8]Kiriyama S, Kozaka K, Takada T, et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci, 2018.PMID 29032610
9. [9]Miura F, Okamoto K, Takada T, et al. Tokyo Guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis. J Hepatobiliary Pancreat Sci, 2018.PMID 28941329
10. [10]Mayumi T, Okamoto K, Takada T, et al. Tokyo Guidelines 2018: management bundles for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci, 2018.PMID 29090868
11. [11]Murata A, Matsuda S, Kuwabara K, et al. Evaluation of compliance with the Tokyo Guidelines for the management of acute cholangitis based on the Japanese administrative database associated with the Diagnosis Procedure Combination system. J Hepatobiliary Pancreat Sci, 2011.PMID 20607569
12. [12]Otani T, Ichiba T, Seo K, et al. Blood cultures should be collected for acute cholangitis regardless of severity. J Infect Chemother, 2022.PMID 34635451
13. [13]He YQ, Wang H, Zhao YH, et al. Nomogram for assistant diagnosing acute suppurative cholangitis: a case-control study. BMC Gastroenterol, 2024.PMID 39304833
14. [14]Gomi H, Solomkin JS, Schlossberg D, et al. Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci, 2018.PMID 29090866
15. [15]Srinu D, Shah J, Jena A, et al. Conventional vs Short Duration of Antibiotics in Patients With Moderate or Severe Cholangitis: Noninferiority Randomized Trial. Am J Gastroenterol, 2024.PMID 37732816
16. [16]Haal S, Ten Böhmer B, Balkema S, et al. Antimicrobial therapy of 3 days or less is sufficient after successful ERCP for acute cholangitis. United European Gastroenterol J, 2020.PMID 32213042
17. [17]Tinusz B, Szapáry L, Paládi B, et al. Short-Course Antibiotic Treatment Is Not Inferior to a Long-Course One in Acute Cholangitis: A Systematic Review. Dig Dis Sci, 2019.PMID 30368681
18. [18]Park TY, Choi JS, Song TJ, et al. Early oral antibiotic switch compared with conventional intravenous antibiotic therapy for acute cholangitis with bacteremia. Dig Dis Sci, 2014.PMID 24898101
19. [19]Lee TS, Choi JH, Lee JM, et al. A randomized non-inferiority trial investigating antibiotic adjustments based on blood culture in acute cholangitis. Clin Microbiol Infect, 2025.PMID 39880122
20. [20]García-Marmolejo JP, Diaz-Brochero C, Nocua-Báez LC, et al. Differences in clinical outcomes according to duration of antibiotic therapy following successful ERCP in patients with acute cholangitis: A retrospective cohort study in Colombia. Infect Dis Now, 2025.PMID 41176092
21. [21]Mukai S, Itoi T, Tsuchiya T, et al. Urgent and emergency endoscopic retrograde cholangiopancreatography for gallstone-induced acute cholangitis and pancreatitis. Dig Endosc, 2023.PMID 35702927
22. [22]Manes G, Paspatis G, Aabakken L, et al. Endoscopic management of common bile duct stones: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy, 2019.PMID 30943551
23. [23]Karvellas CJ, Abraldes JG, Zepeda-Gomez S, et al. The impact of delayed biliary decompression and anti-microbial therapy in 260 patients with cholangitis-associated septic shock. Aliment Pharmacol Ther, 2016.PMID 27506331
24. [24]Du L, Cen M, Zheng X, et al. Timing of Performing Endoscopic Retrograde Cholangiopancreatography and Inpatient Mortality in Acute Cholangitis: A Systematic Review and Meta-Analysis. Clin Transl Gastroenterol, 2020.PMID 32352721
25. [25]Kongsakon R, Rugivarodom M, Phisalprapa P, et al. Urgent endoscopic retrograde cholangiopancreatography improves clinical outcomes in acute cholangitis from choledocholithiasis: a propensity score-matched study. Surg Endosc, 2025.PMID 41023220
26. [26]Seo YJ, Hadaya J, Sareh S, et al. National trends and outcomes in timing of ERCP in patients with cholangitis. Surgery, 2020.PMID 32611515
27. [27]Ayyıldızoğlu T, Gören İ Association of ERCP Timing with Clinical Outcomes in Acute Cholangitis Secondary to Choledocholithiasis: A Retrospective Cohort Study. J Clin Med, 2026.PMID 42590103
28. [28]Park CS, Jeong HS, Kim KB, et al. Urgent ERCP for acute cholangitis reduces mortality and hospital stay in elderly and very elderly patients. Hepatobiliary Pancreat Dis Int, 2016.PMID 27919851
29. [29]Sohail A, Shehadah A, Chaudhary A, et al. Impact of index admission cholecystectomy vs interval cholecystectomy on readmission rate in acute cholangitis: National Readmission Database survey. World J Gastrointest Endosc, 2024.PMID 38946855
30. [30]Chang YR, Wu CH, Chen HW, et al. Optimal Timing of Cholecystectomy for Patients with Concurrent Acute Cholecystitis and Acute Cholangitis after Successful Biliary Drainage by Interventional Endoscopic Retrograde Cholangiopancreatography. J Clin Med, 2022.PMID 36362831
31. [31]Li VK, Yum JL, Yeung YP Optimal timing of elective laparoscopic cholecystectomy after acute cholangitis and subsequent clearance of choledocholithiasis. Am J Surg, 2010.PMID 20381787
32. [32]Ramai D, Heaton J, Ofosu A, et al. Influence of Frailty in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography for Biliary Stone Disease: A Nationwide Study. Dig Dis Sci, 2023.PMID 37368202
33. [33]Kivivuori A, Mattila L, Siiki A, et al. Wait-and-see strategy is justified after ERCP and endoscopic sphincterotomy in elderly patients with common biliary duct stones. J Trauma Acute Care Surg, 2023.PMID 36524923
34. [34]Barbosa EC, Santo PADE, Baraldo S, et al. EUS- versus ERCP-guided biliary drainage for malignant biliary obstruction: a systematic review and meta-analysis of randomized controlled trials. Gastrointest Endosc, 2024.PMID 38648989